Trials / Completed
CompletedNCT04143854
Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Lateral Canthal Lines
Phase II, Randomized, Double-blind, Placebo Controlled, Multi-Center, Dose-ranging and Open Label Extension Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Moderate to Severe Lateral Canthal Lines
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 150 (actual)
- Sponsor
- Medy-Tox · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This phase 2 study includes two treatment period; 1)Dose- ranging period, Day 0 to 16 weeks, which will assess dose-related safety/tolerance, and the potential to improve the appearance of lateral canthal lines and 2) open-label extension period, 16 weeks to 52 weeks, which will evaluate the long term-safety of MBA-P01
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MBA-P01(Botulinum toxin A) | Intramuscular injection; Dose varies by group |
| DRUG | Placebo | Intramuscular injection; normal saline |
Timeline
- Start date
- 2019-05-21
- Primary completion
- 2020-08-19
- Completion
- 2020-08-19
- First posted
- 2019-10-29
- Last updated
- 2021-03-19
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT04143854. Inclusion in this directory is not an endorsement.